More importantly, it is worth to point at the failure of phase II clinical trials in that the inhibition of IL-1α and IL-1β, as well as IL-18 ad P2X7, all underlying NLRP3-dependent and independent inflammasome, did not prove of beneficial activity in COPD patients. The gene discussed is NLRP3; the disease is chronic obstructive pulmonary disease.